Program
silicon dioxide
Also written as “Sodium fluoride / silica and carbopol, 1.5g”, “Colloidal Silicon Dioxide” and “Sodium fluoride / silica and carbopol, 0.5g”.
Its studies are mostly in Dermatitis, Atopic · Dental Caries · Dentin Sensitivity, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Colgate Palmolive | 10 open or running | phase 3since Sep 26, 2008 | Sep 26, 2008 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 4since Feb 16, 2012 | Feb 16, 2012 | none ahead |
| Polisorb Joint Stock | 10 open or running | phase 3since Oct 20, 2026 | Oct 20, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 26, 2008First study: phase 3 study in Dentin SensitivityNew to Colgate PalmoliveColgate Palmolive · NCT00763269 · 626 enrolled · United States
- Feb 16, 2012GlaxoSmithKline's first study: phase 4 study in Dental CariesNew to GlaxoSmithKlineGlaxoSmithKline · NCT01563172 · 65 enrolled · United States
- Oct 20, 2026Polisorb Joint Stock's first study: phase 3 study in Dermatitis, AtopicNew to Polisorb Joint StockPolisorb Joint Stock · NCT07929181 · 161 enrolled · Russia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07929181Dermatitis, Atopic · Russia | 3 | Completed | Polisorb Joint Stock | Nov 28, 2024 | 161 |
| NCT01563172Dental Caries · United States | 4 | Completed | GlaxoSmithKline | Jun 1, 2009 | 65 |
| NCT00763269Dentin Sensitivity · United States | 3 | Completed | Colgate Palmolive | Dec 2008 | 626 |
How it is read
Names in the registry
- “Sodium fluoride / silica and carbopol, 1.5g”, 2 entries
- “Colloidal Silicon Dioxide”, 1 entry
- “Sodium fluoride / silica and carbopol, 0.5g”, 1 entry
- “Triclosan, Silicon dioxide, fluoride”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
- Dental Caries, 1 study
- Dentin Sensitivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.